What is Spencer Pharmaceutical Inc?
develops drug platform technologies for the treatment of neurological deceases.
SPPH · Verdict
Moderate reward · moderate risk
SPPH stands out on cash flow and balance sheet, but watch the volatility signal.
Based on 75% data coverage
SPPH · Verdict
Top decile vs peers
Current ratio 0.28
Weak vs peers
0% return on equity
Model-based scoring. For information only — not financial advice.
develops drug platform technologies for the treatment of neurological deceases. The company specializes in the controlled release of existing therapeutic molecules in the areas of central nervous system, which include Alzheimer and Parkinson diseases, and brain cancer; and patented slow release drug delivery technology for the treatment of type-2 diabetes, arthritis, and other potential applications. The company is listed on the OTCCE in USA, operating in the Healthcare sector, with a market capitalisation of 1.34M.
The scoring profile indicates limited reward potential at this time, with valuation and growth offering the most support. Risk indicators are moderate, consistent with typical market exposure.
For informational purposes only. Not financial advice.